Utah Medical Products Competitors

Utah Medical Products (NASDAQ:UTMD) and Align Technology (NASDAQ:ALGN) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Utah Medical Products has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, Align Technology has a beta of 1.68, meaning that its stock price is 68% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and Align Technology, as reported by MarketBeat.

Align Technology has a consensus target price of $627.0909, indicating a potential upside of 10.20%. Given Align Technology's higher possible upside, analysts plainly believe Align Technology is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and Align Technology's net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 85.8% of Align Technology shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 1.2% of Align Technology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Utah Medical Products and Align Technology's gross revenue, earnings per share and valuation.

Align Technology has higher revenue and earnings than Utah Medical Products.

Summary

Align Technology beats Utah Medical Products on 10 of the 12 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and West Pharmaceutical Services (NYSE:WST) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. West Pharmaceutical Services pays an annual dividend of $0.68 per share and has a dividend yield of 0.2%. West Pharmaceutical Services pays out 21.0% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and West Pharmaceutical Services has increased its dividend for 25 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, West Pharmaceutical Services has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and West Pharmaceutical Services, as reported by MarketBeat.

West Pharmaceutical Services has a consensus target price of $310.00, indicating a potential downside of 6.93%. Given West Pharmaceutical Services' higher possible upside, analysts plainly believe West Pharmaceutical Services is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and West Pharmaceutical Services' net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 92.6% of West Pharmaceutical Services shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 1.6% of West Pharmaceutical Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and West Pharmaceutical Services' revenue, earnings per share and valuation.

West Pharmaceutical Services has higher revenue and earnings than Utah Medical Products.

Summary

West Pharmaceutical Services beats Utah Medical Products on 11 of the 15 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and The Cooper Companies (NYSE:COO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. The Cooper Companies pays an annual dividend of $0.06 per share and has a dividend yield of 0.0%. The Cooper Companies pays out 0.6% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and The Cooper Companies has increased its dividend for 1 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, The Cooper Companies has a beta of 0.82, indicating that its share price is 18% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and The Cooper Companies, as reported by MarketBeat.

The Cooper Companies has a consensus target price of $385.50, indicating a potential downside of 0.95%. Given The Cooper Companies' higher possible upside, analysts plainly believe The Cooper Companies is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and The Cooper Companies' net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 95.8% of The Cooper Companies shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 1.4% of The Cooper Companies shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and The Cooper Companies' revenue, earnings per share and valuation.

The Cooper Companies has higher revenue and earnings than Utah Medical Products.

Summary

The Cooper Companies beats Utah Medical Products on 9 of the 14 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and DENTSPLY SIRONA (NASDAQ:XRAY) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Dividends

Utah Medical Products pays an annual dividend of $1.14 per share and has a dividend yield of 1.3%. DENTSPLY SIRONA pays an annual dividend of $0.40 per share and has a dividend yield of 0.6%. DENTSPLY SIRONA pays out 16.3% of its earnings in the form of a dividend. Utah Medical Products has increased its dividend for 1 consecutive years and DENTSPLY SIRONA has increased its dividend for 1 consecutive years.

Risk & Volatility

Utah Medical Products has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, DENTSPLY SIRONA has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and DENTSPLY SIRONA, as reported by MarketBeat.

DENTSPLY SIRONA has a consensus target price of $62.4444, indicating a potential downside of 7.94%. Given DENTSPLY SIRONA's higher possible upside, analysts plainly believe DENTSPLY SIRONA is more favorable than Utah Medical Products.

Profitability

This table compares Utah Medical Products and DENTSPLY SIRONA's net margins, return on equity and return on assets.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 96.0% of DENTSPLY SIRONA shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by company insiders. Comparatively, 0.5% of DENTSPLY SIRONA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Utah Medical Products and DENTSPLY SIRONA's revenue, earnings per share and valuation.

DENTSPLY SIRONA has higher revenue and earnings than Utah Medical Products.

Summary

Utah Medical Products beats DENTSPLY SIRONA on 8 of the 14 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and STAAR Surgical (NASDAQ:STAA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Risk and Volatility

Utah Medical Products has a beta of 0.29, meaning that its stock price is 71% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Profitability

This table compares Utah Medical Products and STAAR Surgical's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Utah Medical Products and STAAR Surgical's gross revenue, earnings per share and valuation.

Utah Medical Products has higher earnings, but lower revenue than STAAR Surgical.

Analyst Ratings

This is a breakdown of recent recommendations for Utah Medical Products and STAAR Surgical, as reported by MarketBeat.

STAAR Surgical has a consensus target price of $78.40, indicating a potential downside of 29.17%. Given STAAR Surgical's higher possible upside, analysts plainly believe STAAR Surgical is more favorable than Utah Medical Products.

Insider and Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 85.4% of STAAR Surgical shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 3.9% of STAAR Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

STAAR Surgical beats Utah Medical Products on 7 of the 12 factors compared between the two stocks.

Utah Medical Products (NASDAQ:UTMD) and Quidel (NASDAQ:QDEL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, dividends, profitability and risk.

Volatility and Risk

Utah Medical Products has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500. Comparatively, Quidel has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500.

Profitability

This table compares Utah Medical Products and Quidel's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Utah Medical Products and Quidel's revenue, earnings per share (EPS) and valuation.

Quidel has higher revenue and earnings than Utah Medical Products.

Analyst Recommendations

This is a breakdown of recent ratings for Utah Medical Products and Quidel, as reported by MarketBeat.

Quidel has a consensus target price of $182.75, indicating a potential upside of 54.60%. Given Quidel's higher possible upside, analysts plainly believe Quidel is more favorable than Utah Medical Products.

Insider & Institutional Ownership

72.8% of Utah Medical Products shares are held by institutional investors. Comparatively, 84.0% of Quidel shares are held by institutional investors. 7.3% of Utah Medical Products shares are held by insiders. Comparatively, 14.1% of Quidel shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Quidel beats Utah Medical Products on 11 of the 12 factors compared between the two stocks.